1. Home
  2. CSTL vs EVC Comparison

CSTL vs EVC Comparison

Compare CSTL & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

N/A

Current Price

$35.31

Market Cap

722.8M

Sector

Health Care

ML Signal

N/A

Logo Entravision Communications Corporation

EVC

Entravision Communications Corporation

N/A

Current Price

$7.39

Market Cap

683.9M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
CSTL
EVC
Founded
2007
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Broadcasting
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
722.8M
683.9M
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
CSTL
EVC
Price
$35.31
$7.39
Analyst Decision
Strong Buy
Analyst Count
9
0
Target Price
★ $45.11
N/A
AVG Volume (30 Days)
254.6K
★ 935.3K
Earning Date
11-02-2026
11-03-2026
Dividend Yield
N/A
★ 2.72%
EPS Growth
N/A
★ 47.59
EPS
N/A
★ 0.32
Revenue
$344,229,000.00
★ $536,034,000.00
Revenue This Year
$8.41
N/A
Revenue Next Year
$10.30
N/A
P/E Ratio
★ N/A
$23.20
Revenue Growth
★ 3.66
N/A
52 Week Low
$17.72
$1.95
52 Week High
$44.28
$13.74

Technical Indicators

Market Signals
Indicator
CSTL
EVC
Relative Strength Index (RSI) 63.06 30.58
Support Level $33.90 $2.89
Resistance Level $36.85 $10.09
Average True Range (ATR) 1.46 0.29
MACD -0.07 -0.01
Stochastic Oscillator 86.78 7.01

Price Performance

Historical Comparison
CSTL
EVC

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.

Share on Social Networks: